- $27.52m
- $39.67m
- $37.06m
Cytosorbents Corp reports results for the quarter ended in March - Earnings Summary
Brief: Cytosorbents’ Pivotal Star-T Trial Reaches Second Key Milestone With 80 Patients Enrolled
Brief: Cytosorbents Corp - As Previously Disclosed, Kathleen P. Bloch Retired From Her Role As Chief Financial Officer Of Co, Effective As Of March 31, 2023
Brief: Landmark Publication Underscores Robust Ability Of Cytosorb To Reduce Cytokine Storm During Systemic Hyperinflammation
Brief: Cytosorbents Comments On Bank Exposure And Diversified Cash Position
Cytosorbents Corp reports results for the quarter ended in December - Earnings Summary
Brief: Cytosorbents Reports Fourth Quarter And Full Year 2022 Results
Brief: CytoSorbents Reports Fourth Quarter And Full Year 2022 Results
Cytosorbents Corp expected to post a loss of 17 cents a share - Earnings Preview
Brief: CytoSorbents Reports Preliminary Fourth Quarter And Full Year 2022 Revenue
Brief: CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial
Brief: CytoSorbents Receives $5 Mln In Non-Dilutive Debt Financing From Bridge Bank And Extends Loan Agreement
Brief: Independent Data, Safety Monitoring Board Recommends CytoSorbents To Continue STAR-T Trial Without Modifications
Brief: Cytosorbents Announces Pivotal Star-T Trial Reaches First Milestone With 40 Patients Enrolled
U.S. RESEARCH ROUNDUP-Altice USA, C4 Therapeutics, Lincoln National
Cytosorbents Corp reports results for the quarter ended in September - Earnings Summary
Brief: Cytosorbents Reports Third Quarter 2022 Results
Brief: 'Enhanced Lung Rest' With Cytosorb And Ecmo Achieves High Survival In 100 Critically-ill Covid-19 Patients
Cytosorbents Corp expected to post a loss of 16 cents a share - Earnings Preview